摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-bromo-2-cyanobenzenesulfonyl chloride | 1257415-88-5

中文名称
——
中文别名
——
英文名称
5-bromo-2-cyanobenzenesulfonyl chloride
英文别名
5-Bromo-2-cyanobenzene-1-sulfonyl chloride
5-bromo-2-cyanobenzenesulfonyl chloride化学式
CAS
1257415-88-5
化学式
C7H3BrClNO2S
mdl
MFCD18390734
分子量
280.529
InChiKey
BPGQSAVORPJKIJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    394.6±32.0 °C(Predicted)
  • 密度:
    1.94±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    66.3
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    5-bromo-2-cyanobenzenesulfonyl chloride咪唑(1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride二异丁基氢化铝 、 sodium cyanoborohydride 、 sodium carbonate 、 溶剂黄1461,8-二氮杂双环[5.4.0]十一碳-7-烯三氟乙酸 作用下, 以 四氢呋喃1,4-二氧六环甲醇二氯甲烷1,2-二氯乙烷 为溶剂, 反应 36.67h, 生成 2-amino-8-[3-[3-(hydroxymethyl)azetidin-1-yl]sulfonyl-4-(methylaminomethyl)phenyl]-N,N-dipropyl-3H-1-benzazepine-4-carboxamide
    参考文献:
    名称:
    [EN] MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS
    [FR] COMPOSÉS D'AMINOBENZAZÉPINE À SUPPORT MACROMOLÉCULAIRE
    摘要:
    该应用程序提供了由共轭连接到一种或多种氨基苯并二氮杂环衍生物的大分子支持的化合物,其化学式为I或III。该应用程序还提供了具有反应性功能基团的化学式II的氨基苯并二氮杂环衍生物中间体组合物。这种中间体组合物适合通过连接物或连接基团形成大分子支持的化合物。该应用程序还提供了包含大分子支持化合物的组合物,以及使用这些大分子支持化合物治疗癌症的方法。
    公开号:
    WO2020252254A1
  • 作为产物:
    参考文献:
    名称:
    Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Synthesis and structure–activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives
    摘要:
    In a previous study, we described the structure-activity relationships (SARs) for a series of thiazolidenebenzenesulfonamide derivatives. These compounds were found to be highly potent inhibitors of the wild type (WT) and Y181C mutant reverse transcriptases (RTs) and modest inhibitors of K 103N RT. These molecules are thus considered to be a novel class of non-nucleoside HIV-1 RT inhibitors (NNRTIs). In this paper, we have examined the effects of substituents on both the thiazolidene and benzenesulfonamide moieties. Introduction of a 2-cyanophenyl ring into these moieties significantly enhanced anti-HIV-1 activity, whereas a 2-hydroxyphenyl group endowed potent activity against RTs, including K103N and Y181C mutants. Among the series of molecules examined, 101 and 18b (YM-228855), combinations of 2-cyanophenyl and 4-methyl-5-isopropylthiazole moieties, showed extremely potent anti-HIV-1 activity. The EC50 values of 101 and 18b were 0.0017 and 0.0018 muM, respectively. These values were lower than that of efavirenz (3). Compound 11g (YM-215389), a combination of 2-hydroxyphenyl and 4-chloro-5-isopropylthiazole moieties, proved to be the most active against both K103N and Y181C RTs with IC50 values of 0.043 and 0.013 muM, respectively. (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2004.11.045
点击查看最新优质反应信息

文献信息

  • SULFONAMIDE COMPOUND OR SALT THEREOF
    申请人:Taiho Pharmaceutical Co., Ltd.
    公开号:EP3466934A1
    公开(公告)日:2019-04-10
    The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient. A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents -NH-; X4 represents a hydrogen atom or the like; R1 represents -C(R11)(R12)- or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.
    本发明提供了一种具有核糖核苷酸还原酶抑制活性的新型磺酰胺化合物或其盐,以及含有该化合物作为活性成分的药物组合物。 由式(I)代表的化合物[其中,X1代表氧原子或类似物;X2代表氧原子;X3代表-NH-;X4代表氢原子或类似物;R1代表-C(R11)(R12)-或类似物;R11和R12相同或不同且各自代表氢原子或类似物;R2代表任选取代的C6-C14芳烃基团或类似物;R3代表任选取代的C6-C14芳烃基团或类似物;R4代表氢原子或类似物]或其盐。
  • ANTITUMOR AGENT
    申请人:Taiho Pharmaceutical Co., Ltd.
    公开号:EP3718545A1
    公开(公告)日:2020-10-07
    The present invention provides a method of enhancing an antitumor effect by a compound strongly inhibiting ribonucleotide reductase (RNR) or a salt thereof. A combination formulation involving combined administration of a sulfonamide compound represented by Formula (I) [In the formula, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents -NH-; X4 represents a hydrogen atom or the like; R1 represents -C(R11) (R12)- or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof, having RNR inhibitory activity, and other antitumor agent(s).
    本发明提供了一种通过强抑制核糖核苷酸还原酶(RNR)的化合物或其盐增强抗肿瘤效果的方法。 一种组合制剂涉及联合给药由式(I)代表的磺酰胺化合物[式中,X1代表氧原子或类似物;X2代表氧原子;X3代表-NH-;X4代表氢原子或类似物;R1代表-C(R11)(R12)-或类似物;R11和R12相同或不同,各自代表氢原子或类似物;R2代表任选取代的C6-C14芳烃基团或类似物;R3代表任选取代的C6-C14芳烃基团或类似物;R4代表氢原子或类似物]或其盐,具有RNR抑制活性,以及其他抗肿瘤剂。
  • Sulfonamide compound or salt thereof
    申请人:Taiho Pharmaceutical Co., Ltd.
    公开号:US10889555B2
    公开(公告)日:2021-01-12
    The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient. A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents —NH—; X4 represents a hydrogen atom or the like; R1 represents —C(R11)(R12)— or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.
    本发明提供了一种具有核糖核苷酸还原酶抑制活性的新型磺酰胺化合物或其盐,以及含有该化合物作为活性成分的药物组合物。 由式(I)代表的化合物[其中,X1代表氧原子或类似物;X2代表氧原子;X3代表-NH-;X4代表氢原子或类似物;R1代表-C(R11)(R12)-或类似物;R11和R12相同或不同且各自代表氢原子或类似物;R2代表任选取代的C6-C14芳烃基团或类似物;R3代表任选取代的C6-C14芳烃基团或类似物;R4代表氢原子或类似物]或其盐。
  • Kreis, Justus Liebigs Annalen der Chemie, 1895, vol. 286, p. 386
    作者:Kreis
    DOI:——
    日期:——
  • Blanchard, American Chemical Journal, 1903, vol. 30, p. 508
    作者:Blanchard
    DOI:——
    日期:——
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐